Physician profile
Wael K Barsoum
NPI 1326151408
$8,894,546.11
in general payments reported to CMS, 2019-2025
7 companies · $1.9M in 2025
The $1.9M reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $754K · 2020: $786K · 2021: $1.0M · 2022: $1.3M · 2023: $1.5M · 2024: $1.7M · 2025: $1.9M.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $5.0M · Travel and Lodging: $39K · Food and Beverage: $4,529 · Consulting Fee: $2,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $5,032,433.01 |
| Travel and Lodging | $38,759.93 |
| Food and Beverage | $4,528.80 |
| Consulting Fee | $2,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $8,865,229.01 | 2019-2025 | Accolade, Trident, Triathlon |
| Exactech, INC. | $28,865.29 | 2019 | |
| Zimmer Biomet Holdings, INC. | $216.54 | 2019-2021 | |
| Fx Shoulder Solutions, INC | $97.10 | 2021 | |
| Onkos Surgical, INC. | $88.48 | 2025 | Eleos Limb Salvage System |
| Biocomposites INC | $49.69 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wael Barsoum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.